ResearcherArmy Medical UniversityActive in the last 2 years
Yishi Yang
Matched on ORCID iD 0000-0002-9499-4311; OpenAlex author ID A5101577829. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 9
2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper
Papers 6
- NPC1L1 on pancreatic adenocarcinoma cell functions as a two-pronged checkpoint against antitumor activity. Co-author DOI 10.1016/j.xinn.2024.100783↗
- Comment On: Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma. Co-author DOI 10.1097/as9.0000000000000273↗
- Pumilio RNA-Binding Family Member 1 Plays a Promoting Role on Pancreatic Cancer Angiogenesis. Co-author DOI 10.1155/2022/9202531↗
- PUM1 is upregulated by DNA methylation to suppress antitumor immunity and results in poor prognosis in pancreatic cancer. Co-author DOI 10.21037/tcr-20-3295↗
- Human Positive Coactivator 4 Affects the Progression and Prognosis of Pancreatic Ductal Adenocarcinoma via the mTOR/P70s6k Signaling Pathway. First author DOI 10.2147/ott.s284219↗
- PUM1 knockdown prevents tumor progression by activating the PERK/eIF2/ATF4 signaling pathway in pancreatic adenocarcinoma cells. Co-author DOI 10.1038/s41419-019-1839-z↗
Closest collaborators
The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Xingxing Su · 6 shared papers, 2019–2025 · strength 0.91
- Paper Comment On: Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pan… DOI 10.1097/as9.0000000000000273↗
- Paper NPC1L1 on pancreatic adenocarcinoma cell functions as a two-pronged checkpoint against antitumor activity. DOI 10.1016/j.xinn.2024.100783↗
- Paper Pumilio RNA-Binding Family Member 1 Plays a Promoting Role on Pancreatic Cancer Angiogenesis. DOI 10.1155/2022/9202531↗
- Haisu Dai · 5 shared papers, 2019–2025 · strength 0.69
- Paper NPC1L1 on pancreatic adenocarcinoma cell functions as a two-pronged checkpoint against antitumor activity. DOI 10.1016/j.xinn.2024.100783↗
- Paper Pumilio RNA-Binding Family Member 1 Plays a Promoting Role on Pancreatic Cancer Angiogenesis. DOI 10.1155/2022/9202531↗
- Paper PUM1 is upregulated by DNA methylation to suppress antitumor immunity and results in poor prognosis in pancreatic cance… DOI 10.21037/tcr-20-3295↗
- Zhiyu Chen · 3 shared papers, 2019–2023 · strength 0.50
- Paper Comment On: Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pan… DOI 10.1097/as9.0000000000000273↗
- Paper Pumilio RNA-Binding Family Member 1 Plays a Promoting Role on Pancreatic Cancer Angiogenesis. DOI 10.1155/2022/9202531↗
- Paper PUM1 knockdown prevents tumor progression by activating the PERK/eIF2/ATF4 signaling pathway in pancreatic adenocarcino… DOI 10.1038/s41419-019-1839-z↗
- Zhi-Peng Liu · 2 shared papers, 2022–2023 · strength 0.40
- Zhiyu Chen · 2 shared papers, 2020–2021 · strength 0.22
- Paper PUM1 is upregulated by DNA methylation to suppress antitumor immunity and results in poor prognosis in pancreatic cance… DOI 10.21037/tcr-20-3295↗
- Paper Human Positive Coactivator 4 Affects the Progression and Prognosis of Pancreatic Ductal Adenocarcinoma via the mTOR/P70… DOI 10.2147/ott.s284219↗
- Juanjuan Ou · 1 shared paper, 2025 · strength 0.19
- Ruiyang Zi · 1 shared paper, 2025 · strength 0.19
- Yan Jiang · 1 shared paper, 2020 · strength 0.10
- Ping Bie · 1 shared paper, 2019 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.